[FNEplus = Mi-joo Lee] NeoImmuneTech, a global leader in T-cell–based immunotherapies, announced that it has completed a board resolution to secure exclusive North American commercialization and development rights for Endari (L-glutamine) and related generic products, a rare disease therapy for sickle cell disease (SCD) developed by Emmaus Life Sciences, Inc. The agreement is scheduled to be executed on December 24, 2025 (U.S. time).
Endari is an FDA-approved orphan drug that received U.S. Food and Drug Administration approval in 2017 for the treatment of severe complications of sickle cell disease in adult and pediatric patients aged five years and older. Endari works by reducing oxidative stress within red blood cells, improving red blood cell flexibility, and delaying the sickling process, thereby reducing the frequency of vaso-occlusive crises.
Through this licensing transaction, NeoImmuneTech will make a full-scale entry into the U.S. rare disease and specialty pharmaceutical market. Endari is already distributed through major pharmaceutical wholesalers in the United States and is listed with all three major U.S. Pharmacy Benefit Managers (PBMs), enabling stable and ongoing revenue generation. PBMs play a critical role in the U.S. healthcare system by managing formulary access, pricing negotiations, and reimbursement between insurers and pharmacy networks.
NeoImmuneTech expects that this established commercial infrastructure will not only generate stable revenue but also create meaningful synergies in distribution, insurance coverage, and marketing for the future direct commercialization of its proprietary pipeline assets, including NT-I7, in the United States.
The U.S. sickle cell disease patient population is estimated at approximately 100,000 individuals, of whom around 25,000 patients suffer from chronic pain and may be eligible for Endari treatment. Through the acquisition of the Endari license, NeoImmuneTech expects to generate approximately USD 10 million in annual revenue, representing a recurring and sustainable revenue stream rather than a one-time payment. This is considered strategically significant in strengthening the company’s overall financial stability.
Kim Tae-woo, Acting Chief Executive Officer of NeoImmuneTech, stated:
“This exclusive North American license is highly meaningful in that it establishes a foundation for generating revenue and operating profit through the sale of an FDA-approved drug. It not only alleviates market concerns regarding potential designation as an administrative issue stock, but also enables NeoImmuneTech to enter the U.S. pharmaceutical distribution and insurance ecosystem in advance, creating a critical platform to maximize revenue following the future commercialization of NT-I7.”
댓글0